Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aprea Therapeutics, Inc.APRE · Entity 7948 | SVP, Chief Financial Officer | July 28, 2022 | August 01, 2022 |
| LEXICON PHARMACEUTICALS, INC.LXRX · Entity 4970 | SVP, Chief Financial Officer | February 28, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aprea Therapeutics, Inc.
Report date July 28, 2022 · Filed August 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 145,065 |
Reported balance
After 2022-07-28 transaction · row 1
1 source rowRow 1 · 2022-07-28 · Grant · Acquired 60,800 · Balance 145,065 F1: These shares represent restricted stock units which were granted on July 28, 2022, and which will vest and be settled in common stock as follows: (i) 20,266 shares on July 28, 2023, (ii) 20,267 shares on July 28, 2024 and (iii) 20,267 shares on July 28, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. |
| Stock Option (right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.09 · Expires 2032-07-28 | Direct | 89,200 |
Reported balance
After 2022-07-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-07-28 · Grant · Acquired 89,200 · Balance 89,200 F2: Twenty-five percent of these options vest on July 28, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units which were granted on July 28, 2022, and which will vest and be settled in common stock as follows: (i) 20,266 shares on July 28, 2023, (ii) 20,267 shares on July 28, 2024 and (iii) 20,267 shares on July 28, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
F2: Twenty-five percent of these options vest on July 28, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
LEXICON PHARMACEUTICALS, INC.
Report date February 28, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 105,356 |
Ending reported balance
After 2026-02-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-28 · Exercise / conversion · Acquired 160,237 · Balance 160,237 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. Row 2 · 2026-02-28 · Tax withholding · Disposed 54,881 · Balance 105,356 F2: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 320,473 |
Reported balance
After 2026-02-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-28 · Exercise / conversion · Disposed 160,237 · Balance 320,473 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. F3: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock.
F2: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
F3: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AGILE THERAPEUTICS INC
Report date August 26, 2024 · Filed August 26, 2024
Section 16 reporting ended · disclosed 2024-08-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-08-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-08-26 · Disposition to issuer · Disposed 15,000 · Balance 5,080 F1: Upon the consummation of the merger (the "Merger") pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 25, 2024, by and among Agile Therapeutics, Inc. (the "Company"), Insud Pharma, S.L. ("Insud"), and Exeltis Project, Inc., a Delaware corporation and indirect, wholly owned subsidiary of Insud ("Merger Sub"), 15,000 restricted stock units ("Agile RSUs") were cancelled and converted into the right to receive a cash payment of $1.52 (the "Merger Consideration") per Agile RSU, for an aggregate of $22,800, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock subject to such Agile RSU owned by the reporting person. Row 2 · 2024-08-26 · Disposition to issuer · Disposed 5,080 · Balance 0 F2: Upon the consummation of the Merger, pursuant to the Merger Agreement, 5,080 shares of Common Stock were converted into the right to receive the Merger Consideration, for an aggregate of $7,722, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock owned by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the consummation of the merger (the "Merger") pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 25, 2024, by and among Agile Therapeutics, Inc. (the "Company"), Insud Pharma, S.L. ("Insud"), and Exeltis Project, Inc., a Delaware corporation and indirect, wholly owned subsidiary of Insud ("Merger Sub"), 15,000 restricted stock units ("Agile RSUs") were cancelled and converted into the right to receive a cash payment of $1.52 (the "Merger Consideration") per Agile RSU, for an aggregate of $22,800, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock subject to such Agile RSU owned by the reporting person.
F2: Upon the consummation of the Merger, pursuant to the Merger Agreement, 5,080 shares of Common Stock were converted into the right to receive the Merger Consideration, for an aggregate of $7,722, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock owned by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2026 Filed Mar 3, 2026 12:16 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 160,237 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062822-26-000035 · form4.xml · derivative · entry 3 Coiante Scott M · CIK 0001608536 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 320,473 Underlying: Common Stock · 160,237 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. F3 · derivative.expiration_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. Read SEC document |
| February 28, 2026 Filed Mar 3, 2026 12:16 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Tax withholdingCommon Stock | 54,881 | $1.47 | $80,675.07 |
DisclosureSEC source: 0001062822-26-000035 · form4.xml · nonDerivative · entry 2 Coiante Scott M · CIK 0001608536 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,356 F2 · kind: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto. Read SEC document |
| February 28, 2026 Filed Mar 3, 2026 12:16 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 160,237 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062822-26-000035 · form4.xml · nonDerivative · entry 1 Coiante Scott M · CIK 0001608536 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,237 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:06 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 409,020 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001062822-26-000020 · form4.xml · derivative · entry 2 Coiante Scott M · CIK 0001608536 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 409,020 Underlying: Common Stock · 409,020 shares Expires 2036-02-12 F3 · derivative.exercise_date: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:06 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 272,680 | $0.00 | $0.00 |
DisclosureSEC source: 0001062822-26-000020 · form4.xml · derivative · entry 1 Coiante Scott M · CIK 0001608536 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 272,680 Underlying: Common Stock · 272,680 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. F2 · derivative.expiration_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:17 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 480,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-005212 · form4.xml · derivative · entry 2 Coiante Scott M · CIK 0001608536 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 480,710 Underlying: Common Stock · 480,710 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. F3 · derivative.expiration_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:17 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 721,070 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001127602-25-005212 · form4.xml · derivative · entry 1 Coiante Scott M · CIK 0001608536 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 721,070 Underlying: Common Stock · 721,070 shares Expires 2035-02-13 F1 · derivative.exercise_date: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter. Read SEC document |
| January 02, 2025 Filed Jan 2, 2025 21:09 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 230,000 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001127602-25-000084 · form4.xml · derivative · entry 1 Coiante Scott M · CIK 0001608536 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2035-01-02 F1 · derivative.exercise_date: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter. Read SEC document |
| August 26, 2024 Filed Aug 26, 2024 17:42 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Disposition to issuerCommon Stock | 5,080 | $1.52 | $7,721.60 |
DisclosureSEC source: 0001104659-24-092946 · tm2422466-10_4seq1.xml · nonDerivative · entry 2 Coiante Scott M · CIK 0001608536 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · shares: Upon the consummation of the Merger, pursuant to the Merger Agreement, 5,080 shares of Common Stock were converted into the right to receive the Merger Consideration, for an aggregate of $7,722, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock owned by the reporting person. Read SEC document |
| August 26, 2024 Filed Aug 26, 2024 17:42 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Disposition to issuerCommon Stock | 15,000 | $1.52 | $22,800.00 |
DisclosureSEC source: 0001104659-24-092946 · tm2422466-10_4seq1.xml · nonDerivative · entry 1 Coiante Scott M · CIK 0001608536 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,080 F1 · shares: Upon the consummation of the merger (the "Merger") pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 25, 2024, by and among Agile Therapeutics, Inc. (the "Company"), Insud Pharma, S.L. ("Insud"), and Exeltis Project, Inc., a Delaware corporation and indirect, wholly owned subsidiary of Insud ("Merger Sub"), 15,000 restricted stock units ("Agile RSUs") were cancelled and converted into the right to receive a cash payment of $1.52 (the "Merger Consideration") per Agile RSU, for an aggregate of $22,800, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock subject to such Agile RSU owned by the reporting person. Read SEC document |
| October 03, 2023 Filed Oct 4, 2023 16:45 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-106855 · tm2327624-1_4seq1.xml · nonDerivative · entry 1 Coiante Scott M · CIK 0001608536 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,080 F1 · shares: These shares represent restricted stock units ("RSUs") which were granted as an inducement grant to a new hire on October 3, 2023. The RSUs will vest in four equal installments over four years with the first installment vesting on August 16, 2024 and with the RSUs being fully vested on August 16, 2027. Read SEC document |
| July 28, 2022 Filed Aug 1, 2022 17:00 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 89,200 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0001104659-22-084760 · tm2222147-1_4seq1.xml · derivative · entry 2 Coiante Scott M · CIK 0001608536 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,200 Underlying: Common Stock · 89,200 shares Expires 2032-07-28 F2 · derivative.exercise_date: Twenty-five percent of these options vest on July 28, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| July 28, 2022 Filed Aug 1, 2022 17:00 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 60,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-084760 · tm2222147-1_4seq1.xml · nonDerivative · entry 1 Coiante Scott M · CIK 0001608536 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,065 F1 · shares: These shares represent restricted stock units which were granted on July 28, 2022, and which will vest and be settled in common stock as follows: (i) 20,266 shares on July 28, 2023, (ii) 20,267 shares on July 28, 2024 and (iii) 20,267 shares on July 28, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 17:02 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | Tax withholdingCommon Stock | 35,284 | $0.81 | $28,403.62 |
DisclosureSEC source: 0001104659-22-069009 · tm2217848-3_4seq1.xml · nonDerivative · entry 1 Coiante Scott M · CIK 0001608536 · Director · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,265 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 86,067 restricted stock units. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 17:02 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 185,900 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001104659-22-033391 · tm229119-3_4seq1.xml · derivative · entry 2 Coiante Scott M · CIK 0001608536 · Director · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,900 Underlying: Common Stock · 185,900 shares Expires 2032-03-10 F2 · derivative.exercise_date: Twenty-five percent of these options vest on March 10, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 17:02 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 42,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-033391 · tm229119-3_4seq1.xml · nonDerivative · entry 1 Coiante Scott M · CIK 0001608536 · Director · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,549 F1 · shares: These shares represent restricted stock units which were granted on March 10, 2022, and which will vest and be settled in common stock as follows: (i) 14,300 shares on March 10, 2023, (ii) 14,300 shares on March 10, 2024 and (iii) 14,300 shares on March 10, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 17:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | Tax withholdingCommon Stock | 14,817 | $1.74 | $25,781.58 |
DisclosureSEC source: 0001104659-22-028760 · tm227953-2_4seq1.xml · nonDerivative · entry 1 Coiante Scott M · CIK 0001608536 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,649 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 32,167 restricted stock units. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 17:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | Tax withholdingCommon Stock | 7,534 | $3.98 | $29,985.32 |
DisclosureSEC source: 0001104659-21-110596 · tm2126037-2_4seq1.xml · nonDerivative · entry 1 Coiante Scott M · CIK 0001608536 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,466 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 21,166 restricted stock units. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 19:03 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 143,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001140361-21-006728 · form4.xml · derivative · entry 3 Coiante Scott M · CIK 0001608536 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,000 Underlying: Common Stock · 143,000 shares Expires 2031-02-25 F3 · derivative.exercise_date: Twenty-five percent of these options vest on February 25, 2022, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 19:03 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 63,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-006728 · form4.xml · nonDerivative · entry 2 Coiante Scott M · CIK 0001608536 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,000 F2 · shares: These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 21,166 shares on August 25, 2021, (ii) 21,167 shares on February 25, 2022 and (iii) 21,167 shares on August 25, 2022, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 19:03 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 33,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-006728 · form4.xml · nonDerivative · entry 1 Coiante Scott M · CIK 0001608536 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,500 F1 · shares: These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 11,000 shares on February 25, 2022, (ii) 11,000 shares on February 25, 2023 and (iii) 11,000 shares on February 25, 2024, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| March 24, 2020 Filed Mar 26, 2020 17:00 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 55,000 | $0.00 Strike: $35.50 | $0.00 |
DisclosureSEC source: 0001104659-20-038875 · a4.xml · derivative · entry 1 Coiante Scott M · CIK 0001608536 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2030-03-24 F1 · derivative.exercise_date: Twenty-five percent of these options vest on March 24, 2021, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| October 07, 2019 Filed Oct 7, 2019 19:15 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 150,824 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001140361-19-018071 · form4.xml · derivative · entry 2 Coiante Scott M · CIK 0001608536 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,824 Underlying: Common Stock · 150,824 shares Expires 2029-10-02 F1 · derivative.exercise_date: Twenty-five percent of these options vest on October 2, 2020, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| October 07, 2019 Filed Oct 7, 2019 19:15 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseCommon Stock | 2,500 | $15.00 | $37,500.00 |
DisclosureSEC source: 0001140361-19-018071 · form4.xml · nonDerivative · entry 1 Coiante Scott M · CIK 0001608536 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 17:30 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 38,500 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001104659-19-004818 · a4.xml · derivative · entry 2 Coiante Scott M · CIK 0001608536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,500 Underlying: Common Stock · 38,500 shares Expires 2029-01-28 F1 · derivative.exercise_date: This option was granted on January 29, 2019. 25% of the shares subject to the stock option vest on January 29, 2020, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on January 29, 2023. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 17:30 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 172,600 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001104659-19-004818 · a4.xml · derivative · entry 1 Coiante Scott M · CIK 0001608536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,600 Underlying: Common Stock · 172,600 shares Expires 2029-01-28 F1 · derivative.exercise_date: This option was granted on January 29, 2019. 25% of the shares subject to the stock option vest on January 29, 2020, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on January 29, 2023. Read SEC document |
| January 25, 2019 Filed Jan 28, 2019 17:30 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Exercise / conversionRestricted Stock Units · Derivative | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-003715 · a4.xml · derivative · entry 4 Coiante Scott M · CIK 0001608536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: On January 25, 2017, the reporting person was granted 35,000 restricted stock units that vest as follows: 17,500 units vested and were delivered on January 25, 2018, and 17,500 units vested and were delivered on January 25, 2019. F3 · derivative.expiration_date: On January 25, 2017, the reporting person was granted 35,000 restricted stock units that vest as follows: 17,500 units vested and were delivered on January 25, 2018, and 17,500 units vested and were delivered on January 25, 2019. Read SEC document |
| January 25, 2019 Filed Jan 28, 2019 17:30 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Exercise / conversionCommon Stock | 17,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-003715 · a4.xml · nonDerivative · entry 2 Coiante Scott M · CIK 0001608536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| January 24, 2019 Filed Jan 28, 2019 17:30 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Exercise / conversionRestricted Stock Units · Derivative | 16,070 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-003715 · a4.xml · derivative · entry 3 Coiante Scott M · CIK 0001608536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 16,070 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: On January 24, 2018 the reporting person was granted 16,070 restricted stock units that fully vested and were delivered on January 24, 2019. F2 · derivative.expiration_date: On January 24, 2018 the reporting person was granted 16,070 restricted stock units that fully vested and were delivered on January 24, 2019. Read SEC document |
| January 24, 2019 Filed Jan 28, 2019 17:30 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Exercise / conversionCommon Stock | 16,070 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-003715 · a4.xml · nonDerivative · entry 1 Coiante Scott M · CIK 0001608536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| June 20, 2018 Filed Jun 21, 2018 17:31 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001104659-18-041580 · a4.xml · derivative · entry 1 Coiante Scott M · CIK 0001608536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-06-19 F1 · derivative.exercise_date: This option was granted on June 20, 2018. 25% of the shares subject to the stock option vested on the date of grant. The remaining shares vest in 3 equal 25% installments on December 31, 2018, June 30, 2019 and December 31, 2019. Read SEC document |
| January 25, 2018 Filed Jan 26, 2018 17:16 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Exercise / conversionRestricted Stock Units · Derivative | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-004318 · a4.xml · derivative · entry 5 Coiante Scott M · CIK 0001608536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,570 Underlying: Common Stock · 17,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: The restricted stock units were granted on January 25, 2017 and vest as follows: 17,500 units vested and were delivered on January 25, 2018, and 17,500 units will vest and be delivered on January 25, 2019. F4 · derivative.expiration_date: The restricted stock units were granted on January 25, 2017 and vest as follows: 17,500 units vested and were delivered on January 25, 2018, and 17,500 units will vest and be delivered on January 25, 2019. Read SEC document |
| January 25, 2018 Filed Jan 26, 2018 17:16 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Tax withholdingCommon Stock | 6,753 | $3.32 | $22,419.96 |
DisclosureSEC source: 0001104659-18-004318 · a4.xml · nonDerivative · entry 2 Coiante Scott M · CIK 0001608536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,686 Read SEC document |
| January 25, 2018 Filed Jan 26, 2018 17:16 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Exercise / conversionCommon Stock | 17,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-004318 · a4.xml · nonDerivative · entry 1 Coiante Scott M · CIK 0001608536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,439 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 17:16 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantRestricted Stock Units · Derivative | 16,070 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-004318 · a4.xml · derivative · entry 4 Coiante Scott M · CIK 0001608536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,070 Underlying: Common Stock · 16,070 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: The restricted stock units were granted on January 24, 2018 and will be fully vested and delivered on January 24, 2019. F3 · derivative.expiration_date: The restricted stock units were granted on January 24, 2018 and will be fully vested and delivered on January 24, 2019. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 17:16 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Options (Right to Buy) · Derivative | 107,000 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0001104659-18-004318 · a4.xml · derivative · entry 3 Coiante Scott M · CIK 0001608536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,000 Underlying: Common Stock · 107,000 shares Expires 2028-01-23 F2 · derivative.exercise_date: This option was granted on January 24, 2018. 25% of the shares subject to the stock option vest on January 24, 2019, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on January 24, 2022. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 16:33 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantRestricted Stock Units · Derivative | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-004568 · a4.xml · derivative · entry 2 Coiante Scott M · CIK 0001608536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: The restricted stock units were granted on January 25, 2017 and vest as follows: 17,500 units will vest and be delivered on January 25, 2018, and 17,500 units will vest and be delivered on January 25, 2019. F3 · derivative.expiration_date: The restricted stock units were granted on January 25, 2017 and vest as follows: 17,500 units will vest and be delivered on January 25, 2018, and 17,500 units will vest and be delivered on January 25, 2019. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 16:33 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.26 | $0.00 |
DisclosureSEC source: 0001104659-17-004568 · a4.xml · derivative · entry 1 Coiante Scott M · CIK 0001608536 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-01-24 F2 · derivative.exercise_date: This option was granted on January 25, 2017. 25% of the shares subject to the stock option vest on January 25, 2018, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on January 25, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.